|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current management of hepatocellular carcinoma:An Eastern perspective显示文摘Hepatocellular carcinoma(HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization( TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress. | Hyung Joon Yim Sang Jun Suh Soon Ho Um | 2015 | World Journal of Gastroenterology2015，21，13： | 26 |
| 2 | Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B显示文摘AIM:To investigate retrospectively the long-term efficacy of various treatment strategies using adefovir dipivoxil(adefovir) in patients with lamivudine-resistant chronic hepatitis B.METHODS:We included 154 consecutive patients in two treatment groups:the 'add-on' group(n = 79),in which adefovir was added to ongoing lamivudine treatment due to lamivudine resistance,and the 'switch/combination' group(n = 75),in which lamivudine was first switched to adefovir and then re-added later as needed.The 'switch/combination' group was then divided into two subgroups depending on whether participants followed(group A,n = 30) or violated(group B,n = 45) a proposed treatment strategy that determined whether to add lamivudine based on the serum hepatitis B virus(HBV) DNA levels(< 60 IU/mL or not) after 6 mo of treatment(roadmap concept).RESULTS:The cumulative probability of virologic response(HBV DNA < 60 IU/mL) was higher in group A than in the 'add-on' group and in group B(P < 0.001).In contrast,the cumulative probability of virologic breakthrough was lower in the 'add-on' group than in group B(P = 0.002).Furthermore,the risk of virologic breakthrough in the multivariate analysis was significantly lower in the 'add-on' group than in group A(hazard ratio = 0.096;95%CI,0.015-0.629;P = 0.015).CONCLUSION:The selective combination of adefovir with lamivudine based upon early treatment responses increased the odds of virologic breakthrough relative to the use of uniform combination therapy from the beginning of treatment. | Tae Jung Yun Jin Yong Jung Chang Ha Kim Soon Ho Um Hyonggin An Yeon Seok Seo Jin Dong Kim Hyung Joon Yim Bora Keum Yong Sik Kim Yoon Tae Jeen Hong Sik Lee Hoon Jai Chun Chang Duck Kim Ho Sang Ryu | 2012 | World Journal of Gastroenterology2012，18，47： | 19 |
| 3 | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies显示文摘AIM: To evaluate the long-term efficacy adefovir(ADV)-based combination therapies in entecavir(ETV)-resistant chronic hepatitis B(CHB) patients. METHODS: F i fty CHB pat ient s wi t h genotypic resistance to ETV at 13 medical centers in South Korea were included for the analysis. All the patients received rescue therapy with the combination of ADV plus ETV(ADV/ETV,n = 23) or ADV plus lamivudine(LMV)(ADV/LMV,n = 27) for more than 12 mo. Patients were monitored at least every 3-4 mo during ADV-based combination therapy by clinical examination as well as biochemical and virological assessments. Hepatitis B virus(HBV) DNA levels were measured by realtime PCR and logarithmically transformed for analysis. Cumulative rates of virologic response(VR; HBV DNA < 20 IU/m L) were calculated using the Kaplan-Meier method,and the difference was determined by a logrank test. Multivariate logistic regression and Cox proportional hazards models were used to identify independent risk factors significantly associated with short-term and long-term VR,respectively.RESULTS: Baseline median HBV DNA levels were 5.53(2.81-7.63) log10 IU/m L. The most commonly observed ETV genotypic mutation sites were rt184 and rt202. Patients were treated for a median of 27(12-45) mo. Overall,cumulative VR rates at 6,12,24,and 36 mo were 26%,36%,45%,and 68%,respectively. Patients treated with the ADV/ETV combination showed higher cumulative VR rates(35%,43%,65%,and 76%,respectively) than those with the ADV/LAM combination(18%,30%,30%,and 62%,respectively; P = 0.048). In the multivariate analysis,low baseline HBV DNA levels(< 5.2 log10 IU/m L) and initial virologic response at 3 mo(IVR-3; HBV DNA < 3.3 log10 IU/m L after 3 mo) were independent predictive factors for VR. Patients with favorable predictors achieved cumulative VR rates up to 90% at 36 mo. During the same period,the cumulative incidence of virologic breakthrough was as low as 6% in patients with the both favorable predictors.CONCLUSION: If tenofovir is not available,ADV/ETV combination could be considered in ETV-resistant patients with low HBV DNA titers,and may becontinued if IVR-3 is achieved. | Hyoung Su Kim Hyung Joon Yim Myoung Kuk Jang Ji Won Park Sang Jun Suh Yeon Seok Seo Ji Hoon Kim Bo Hyun Kim Sang Jong Park Sae Hwan Lee Sang Gyune Kim Young Seok Kim Jung Il Lee Jin-Woo Lee In Hee Kim Tae Yeob Kim Jin-Wook Kim Sook-Hyang Jeong Young Kul Jung Hana Park Seong Gyu Hwang | 2015 | World Journal of Gastroenterology2015，21，38： | 13 |
| 4 | Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease显示文摘AIM: To evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors(PPAR)-δ agonist treatment in nonalcoholic fatty liver disease(NAFLD) models.METHODS: Male C57BL/6J mice were classified according to control or high fat diet(HFD) with or without PPAR-δ agonist(GW) over period of 12 wk [control, HFD, HFD + lipopolysaccharide(LPS), HFD + LPS + GW group]. Hep G2 cells were exposed to palmitic acid(PA) and/or LPS in the absence or presence of GW.RESULTS: HFD caused glucose intolerance and hepatic steatosis. In mice fed an HFD with LPS, caspase-1 and interleukin(IL)-1β in the liver were significantly increased. Treatment with GW ameliorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In Hep G2 cells, PA and LPS treatment markedly increased m RNA of several nucleotide-binding andoligomerization domain-like receptor family members(NLRP3, NLRP6, and NLRP10), caspase-1 and IL-1β. PA and LPS also exaggerated reactive oxygen species production. All of the above effects of PA and LPS were reduced by GW. GW also enhanced the phosphorylation of AMPK-α.CONCLUSION: PPAR-δ agonist reduces fatty acidinduced inflammation and steatosis by suppressing inflammasome activation. Targeting the inflammasome by the PPAR-δ agonist may have therapeutic implication for NAFLD. | Hyun Jung Lee Jong Eun Yeon Eun Jung Ko Eileen L Yoon Sang Jun Suh Keunhee Kang Hae Rim Kim Seoung Hee Kang Yang Jae Yoo Jihye Je Beom Jae Lee Ji Hoon Kim Yeon Seok Seo Hyung Joon Yim Kwan Soo Byun | 2015 | World Journal of Gastroenterology2015，21，45： | 9 |
| 5 | Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis显示文摘AIM To assess the performance of proposed scores specific for acute-on-chronic liver failure in predicting shortterm mortality among patients with alcoholic hepatitis.METHODS We retrospectively collected data from 264 patients with clinically diagnosed alcoholic hepatitis from January to December 2013 at 21 academic hospitals in Korea. The performance for predicting short-term mortality was calculated for Chronic Liver FailureSequential Organ Failure Assessment(CLIF-SOFA), CLIF Consortium Organ Failure score(CLIF-C OFs), Maddrey'sdiscriminant function(DF), age, bilirubin, international normalized ratio and creatinine score(ABIC), Glasgow Alcoholic Hepatitis Score(GAHS), model for end-stage liver disease(MELD), and MELD-Na.RESULTS Of 264 patients, 32(12%) patients died within 28 d. The area under receiver operating characteristic curve of CLIF-SOFA, CLIF-C OFs, DF, ABIC, GAHS, MELD, and MELD-Na was 0.86(0.81-0.90), 0.89(0.84-0.92), 0.79(0.74-0.84), 0.78(0.72-0.83), 0.81(0.76-0.86), 0.83(0.78-0.88), and 0.83(0.78-0.88), respectively, for 28-d mortality. The performance of CLIF-SOFA had no statistically significant differences for 28-d mortality. The performance of CLIF-C OFs was superior to that of DF, ABIC, and GAHS, while comparable to that of MELD and MELD-Na in predicting 28-d mortality. A CLIF-SOFA score of 8 had 78.1% sensitivity and 79.7% specificity, and CLIF-C OFs of 10 had 68.8% sensitivity and 91.4% specificity for predicting 28-d mortality.CONCLUSION CLIF-SOFA and CLIF-C OF scores performed well, with comparable predictive ability for short-term mortality compared to the commonly used scoring systems in patients with alcoholic hepatitis. | Hee Yeon Kim Chang Wook Kim Tae Yeob Kim Do Seon Song Dong Hyun Sinn Eileen L Yoon Young Kul Jung Ki Tae Suk Sang Soo Lee Chang Hyeong Lee Tae Hun Kim Jeong Han Kim Hyung Joon Yim Sung Eun Kim Soon Koo Baik Byung Seok Lee Jae Young Jang Young Seok Kim Sang Gyune Kim Jin Mo Yang Joo Hyun Sohn Heon Ju Lee Seung Ha Park Eun Hee Choi Dong Joon Kim Korean Acute-on-Chronic Liver Failure Study Group | 2016 | World Journal of Gastroenterology2016，22，41： | 5 |
| 6 | Computed tomography findings for predicting severe acute hepatitis with prolonged cholestasis显示文摘AIM: To evaluate the significance of computed tomography (CT) findings in relation to liver chemistry and the clinical course of acute hepatitis. METHODS: Four hundred and twelve patients with acute hepatitis who underwent enhanced CT scanning were enrolled retrospectively. Imaging findings were analyzed for the following variables: gallbladder wall thickness (GWT), arterial heterogeneity, periportal tracking, number and maximum size of lymph nodes, presence of ascites, and size of spleen. The serum levels of alanine aminotransferase, alkaline phosphatase, bilirubin, albumin, and prothrombin time were measured on the day of admission and CT scan, and laboratory data were evaluated every 2-4 d for all subjects during hospitalization. RESULTS: The mean age of patients was 34.4 years, and the most common cause of hepatitis was hepatitis A virus (77.4%). The mean GWT was 5.2 mm. The number of patients who had findings of arterial heterogeneity, periportal tracking, lymph node enlargement > 7 mm, and ascites was 294 (80.1%), 348 (84.7%), 346 (84.5%), and 56 (13.6%), respectively. On multivariate logistic regression, male gender [odds ratio (OR) = 2.569, 95%CI: 1.477-4.469, P = 0.001], toxic hepatitis (OR = 3.531, 95%CI: 1.444-8.635, P = 0.006), level of albumin (OR = 2.154, 95%CI: 1.279-3.629, P = 0.004), and GWT (OR = 1.061, 95%CI: 1.015-1.110, P = 0.009) were independent predictive factors for severe hepatitis. The level of bilirubin (OR = 1.628, 95%CI: 1.331-1.991, P < 0.001) and GWT (OR = 1.172, 95%CI: 1.024-1.342,P = 0.021) were independent factors for prolonged cholestasis in multivariate analysis. CONCLUSION: In patients with acute hepatitis, GWT on CT scan was an independent predictor of severe hepatitis and prolonged cholestasis. | Sang Jung Park Jin Dong Kim Yeon Seok Seo Beom Jin Park Min Ju Kim Soon Ho Um Chang Ha Kim Hyung Joon Yim Soon Koo Baik Jin Yong Jung Bora Keum Yoon Tae Jeen Hong Sik Lee Hoon Jai Chun Chang Duck Kim Ho Sang Ryu | 2013 | World Journal of Gastroenterology2013，19，16： | 4 |
| 7 | Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions显示文摘 | Sang Hoon Ahn Henry L. Y. Chan Pei-Jer Chen Jun Cheng Mahesh K. Goenka Jinlin Hou Seng Gee Lim Masao Omata Teerha Piratvisuth Qing Xie Hyung Joon Yim Man-Fung Yuen | 2010 | Hepatology International2010，，1： | 3 |
| 8 | Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery显示文摘AIM To investigate the factors affecting diagnostic delay and outcomes of diagnostic delay in inflammatory bowel disease(IBD) METHODS We retrospectively studied 165 patients with Crohn's disease(CD) and 130 patients with ulcerative colitis(UC) who were diagnosed and had follow up durations > 6 mo at Korea University Ansan Hospital from January 2000 to December 2015. A diagnostic delay was defined as the time interval between the first symptom onset and IBD diagnosis in which the 76^(th) to 100^(th) percentiles of patients were diagnosed.RESULTS The median diagnostic time interval was 6.2 and 2.4 mo in the patients with CD and UC, respectively. Among the initial symptoms, perianal discomfort before diagnosis(OR = 10.2, 95%CI: 1.93-54.3, P = 0.006) was associated with diagnostic delays in patients with CD; however, no clinical factor was associated with diagnostic delays in patients with UC. Diagnostic delays, stricturing type, and penetrating type were associated with increased intestinal surgery risks in CD(OR = 2.54, 95%CI: 1.06-6.09; OR = 4.44, 95%CI: 1.67-11.8; OR = 3.79, 95%CI: 1.14-12.6, respectively). In UC, a diagnostic delay was the only factor associated increased intestinal surgery risks(OR = 6.81, 95%CI: 1.12-41.4).CONCLUSION A diagnostic delay was associated with poor outcomes, such as increased intestinal surgery risks in patients with CD and UC. | Dong-won Lee Ja Seol Koo Jung Wan Choe Sang Jun Suh Seung Young Kim Jong Jin Hyun Sung Woo Jung Young Kul Jung Hyung Joon Yim Sang Woo Lee | 2017 | World Journal of Gastroenterology2017，23，35： | 3 |
| 9 | Comparison of Clevudine and Entecavir for Treatment-naive Patients With Chronic Hepatitis B Virus Infection: Two-Year Follow-up Data显示文摘 | Eileen L. Yoon Hyung Joon Yim Hyun Jung Lee Young Sun Lee Jeong Han Kim Eun Suk Jung Ji Hoon Kim Yeon Seok Seo Jong Eun Yeon Hong Sik Lee Soon Ho Um Kwan Soo Byun | 2011 | Journal of Clinical Gastroenterology2011，，10： | 3 |
| 10 | Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma显示文摘BACKGROUND Diagnostic accuracy of various tumor markers and their combinations for hepatocellular carcinoma(HCC)was not fully investigated.AIM To evaluate the diagnostic accuracy of alpha-fetoprotein(AFP),the Lens culinaris agglutinin-reactive fraction of AFP(AFP-L3),and protein induced by vitamin K absence or antagonist-II(PIVKA-II)and their combination for HCC diagnosis.METHODS Patients with newly detected liver mass or elevated serum AFP levels were considered eligible.Serum AFP level,AFP-L3 fraction,and PIVKA-II level were measured at the first visit.RESULTS In total,622 patients were included;355 patients(57.1%)had chronic liver disease,and 208(33.4%)had liver cirrhosis.HCC was diagnosed in 160 patients(25.7%).The area under the receiver operating characteristics curves(AUROCs)of the serum AFP,AFP-L3 fraction,AFP-L3,and PIVKA-II levels for the diagnosis of HCC were 0.775,0.792,0.814,and 0.834,respectively.A novel diagnostic model was developed by classifying patients in a 1:1 ratio into training and validation sets.Using the binary regression analysis of the training cohort,the AFP,AFP-L3 fraction,and PIVKA-II(ALPs)score was calculated as follows:ALPs score=3.8×[serum AFP level(ng/mL)×AFP-L3 fraction(%)×0.01]+0.2×PIVKA-II level(mAU/mL).The AUROC of the ALPs score for diagnosis of HCC was 0.878,significantly higher than that of serum AFP level(P<0.001),AFP-L3 fraction(P<0.001),PIVKA-II level(P=0.036),and AFP-L3 level(P=0.006).The optimal ALPs score cut-off was 5.3(sensitivity,85.0%,specificity 80.1%).The validation cohort showed similar results.CONCLUSION The ALPs score calculated using serum AFP level,AFP-L3 fraction,and PIVKA-II level showed improved accuracy in HCC diagnosis. | Han Ah Lee Yoo Ra Lee Young-Sun Lee Young Kul Jung Ji Hoon Kim Hyunggin An Hyung Joon Yim Yoon Tae Jeen Jong Eun Yeon Kwan Soo Byun Yeon Seok Seo | 2021 | World Journal of Gastroenterology2021，27，28： | 2 |
| 11 | Adding adefovir vs. switching to entecavir for lamivudine‐resistant chronic hepatitis B ( ACE study): a 2‐year follow‐up randomized controlled trial显示文摘 | Hyung Joon Yim Yeon Seok Seo Eileen L. Yoon Chang Wook Kim Chang Don Lee Sang Hoon Park Myung Seok Lee Choong Kee Park Hee Bok Chae Moon Young Kim Soon Koo Baik Yun Soo Kim Ju Hyun Kim Jung Il Lee Jin Woo Lee Sun Pyo Hong Soon Ho Um | 2013 | Liver Int2013，，2： | 2 |
| 12 | Comparative Study of Helicobacter pylori Eradication Rates With 5-day Quadruple “Concomitant” Therapy and 7-day Standard Triple Therapy显示文摘 | Seung Young Kim Sang Woo Lee Jong Jin Hyun Sung Woo Jung Ja Seol Koo Hyung Joon Yim Jong Jae Park Hoon Jai Chun Jai Hyun Choi | 2013 | Journal of Clinical Gastroenterology2013，，1： | 2 |
| 13 | Adefovir and Lamivudine Combination Therapy in Patients with Entecavir-Resistant Chronic Hepatitis B: Antiviral Responses and Evolution of Mutations显示文摘 | Yim Hyung Joon Lee Hyun Jung Suh Sang Jun Seo Yeon Seok Kim Chang Wook Lee Chang Don Park Sang Hoon Lee Myung Seok Park Choong Kee Chae Hee Bok Kim Moon Young Baik Soon Koo Kim Yun Soo Kim Ju Hyun Lee Jung Il Lee Jin Woo Hong Sun Pyo Um | 2014 | Intervirology2014，，5： | 1 |
| 14 | Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation显示文摘 | Ji Hoon Kim Sun Jae Lee Moon Kyung Joo Chung Ho Kim Jong Hwan Choi Young Kul Jung Hyung Joon Yim Jong Eun Yeon Jong-Jae Park Jae Seon Kim Young Tae Bak Kwan Soo Byun | 2009 | Digestive Diseases and Sciences2009，，7： | 1 |
| 15 | Psychometric Hepatic Encephalopathy Score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis显示文摘 | Yeon Seok Seo Sun Young Yim Jin Yong Jung Chang Ha Kim Jin Dong Kim Bora Keum Hyonggin An Hyung Joon Yim Hong Sik Lee Chang Duck Kim Ho Sang Ryu Soon Ho Um | 2012 | Journal of Gastroenterology and Hepatology2012，，11： | 1 |
| 16 | Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization显示文摘 | Eun Suk Jung Ji Hoon Kim Eileen L. Yoon Hyun Jung Lee Soon Jae Lee Sang Jun Suh Beom Jae Lee Yeon Seok Seo Hyung Joon Yim Tae-Seok Seo Chang Hee Lee Jong Eun Yeon Jong-Jae Park Jae Seon Kim Young Tae Bak Kwan Soo Byun | 2013 | Journal of Hepatology2013，，6： | 1 |
| 17 | A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma显示文摘 | Hyun Young Woo Si Hyun Bae Jun Yong Park Kwang Hyub Han Ho Jong Chun Byung Gil Choi Hyeon U. Im Jong Young Choi Seung Kew Yoon Jae Youn Cheong Sung Won Cho Byoung Kuk Jang Jae Seok Hwang Sang Gyune Kim Young Seok Kim Yeon Seok Seo Hyung Joon Yim Soon Ho U | 2010 | Cancer Chemotherapy and Pharmacology2010，，2： | 1 |
| 18 | Prognosis of hepatitis B‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents显示文摘 | Chang Ha Kim Soon Ho Um Yeon Seok Seo Jin Yong Jung Jin Dong Kim Hyung Joon Yim Bora Keum Yong Sik Kim Yoon Tae Jeen Hong Sik Lee Hoon Jai Chun Chang Duck Kim Ho Sang Ryu | 2012 | Journal of Gastroenterology and Hepatology2012，，10： | 1 |
| 19 | Clinical Significance of Hepatitis B Virus Precore and Core Promoter Variants in Korean Patients With Chronic Hepatitis B显示文摘 | Sun Young Yim Soon Ho Um Jin Young Jung Tae Hyung Kim Jin Dong Kim Bora Keum Yeon Seok Seo Hyung Joon Yim Yoon Tae Jeen Hong Sik Lee Hoon Jai Chun Chang Duck Kim Ho Sang Ryu | 2015 | Journal of Clinical Gastroenterology2015，，1： | 1 |
| 20 | A nationwide seroepidemiology of hepatitis C virus infection in South Korea显示文摘 | Do Young Kim In Hee Kim Sook‐Hyang Jeong Yong Kyun Cho Joon Hyoek Lee Young‐Joo Jin Don Lee Dong Jin Suh Kwang‐Hyub Han Neung Hwa Park Ha Yan Kang Young Kul Jung Young Seok Kim Kyung‐Ah Kim Youn Jae Lee Byung Seok Lee Hyung Joon Yim Heon Ju Lee Soon Koo B | 2013 | Liver Int2013，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员